Evaluating the effect of splitting cylindrical power on improving patient tolerance to toric lens misalignment.

Cont Lens Anterior Eye

Aston University, School of Life and Health Sciences, Ophthalmic Research Group, Birmingham B4 7ET, UK. Electronic address:

Published: June 2014

Purpose: Evaluating the impact of splitting toric power on patient tolerance to misorientation such as with intraocular lens rotation.

Setting: University vision clinic.

Methods: Healthy, non astigmats had +1.50D astigmatism induced with spectacle lenses at 90°, 135°, 180° and +3.00D at 90°. Two correcting cylindrical lenses of the opposite sign and half the power each were subsequently added to the trial frame misaligned by 0°, 5° or 10° in a random order and misorientated from the initial axis in a clockwise direction by up to 15° in 5° steps. A second group of adapted astigmats with between 1.00 and 3.00DC had their astigmatism corrected with two toric spectacle lenses of half the power separated by 0°, 5° or 10° and misorientated from the initial axis in both directions by up to 15° in 5° steps. Distance, high contrast visual acuity was measured using a computerised test chart at each lens misalignment and misorientation.

Results: Misorientation of the split toric lenses caused a statistically significant drop in visual acuity (F=70.341; p<0.001). Comparatively better acuities were observed around 180°, as anticipated (F=3.775; p=0.035). Misaligning the split toric power produced no benefit in visual acuity retention with axis misorientation when subjects had astigmatism induced with a low (F=2.190, p=0.129) or high cylinder (F=0.491, p=0.617) or in the adapted astigmats (F=0.120, p=0.887).

Conclusion: Misalignment of toric lens power split across the front and back lens surfaces had no beneficial effect on distance visual acuity, but also no negative effect.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clae.2013.10.002DOI Listing

Publication Analysis

Top Keywords

patient tolerance
8
lens misalignment
8
spectacle lenses
8
half power
8
0° 5°
8
5° 10°
8
misorientated initial
8
initial axis
8
15° 5°
8
5° steps
8

Similar Publications

Background Introduction: Vestibular schwannoma (VS) tumors typically present with sensorineural hearing loss (SNHL). Losartan has recently demonstrated prevention of tumor-associated SNHL in a mouse model of VS through suppression of inflammatory and pro-fibrotic factors, and the current study investigates this association in humans.

Methods: This is a retrospective study of patients with unilateral VS and hypertension followed with sequential audiometry at a tertiary referral hospital from January 1994 to June 2023.

View Article and Find Full Text PDF

Rationale: Patients with atrial fibrillation and a large goiter have high perioperative risks and often cannot tolerate general anesthesia, making it necessary for us to explore new safe and effective anesthesia methods.

Patient Concerns: The patient presented with atrial fibrillation accompanied by rapid ventricular rate, a thrombus attached to the left atrial appendage, and a massive thyroid goiter compressing the airway.

Diagnosis: After the left humerus fracture surgery, the patient's internal fixation loosened and fractured, accompanied by infection, formation of sinus tracts, and suppuration.

View Article and Find Full Text PDF

Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is essential for the survival and immune sequestration of cancer cells. We conducted a phase 1 study of TTI‑101, a first-in-class, selective small-molecule inhibitor of STAT3, in patients with advanced metastatic cancer.

Patients And Methods: Patients were treated with TTI-101 orally twice daily in 28-day cycles at 4 dose levels (DLs): 3.

View Article and Find Full Text PDF

Safety and efficacy of roflumilast cream 0.15% for atopic dermatitis (AD) were demonstrated in two 4-week phase 3 trials. Evaluate long-term safety, tolerability, and efficacy of roflumilast cream 0.

View Article and Find Full Text PDF

Apatinib and trastuzumab-based chemotherapy for heavily treated primary trastuzumab-resistant metastatic breast cancer.

J Cancer Res Ther

December 2024

Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People's Republic of China.

Article Synopsis
  • The study examines the effects of a combination therapy (apatinib and trastuzumab-based chemotherapy) on patients with primary trastuzumab resistance (PTR) in HER2-positive breast cancer.
  • A total of 20 PTR patients were treated, showing a clinical benefit rate of 55%, though no complete responses were observed, and median progression-free survival was 5.7 months.
  • While the treatment had manageable side effects, further research is recommended to better identify which PTR patients could potentially benefit from this therapy.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!